In addition, afatinib inhibits EGFR-mediated PI3K/AKT/mTOR signaling in vitro and in vivo in neuroblastoma cells [30] and inhibits tumorigenesis in glioblastoma by inhibiting EGFR/AKT signaling [31]. This evidence concerns the gene AKT1 and glioblastoma.